Fridge-Free Tetanus and Diphtheria Vaccine Shows Promise in Phase 1 Trials, Advances to Next Clinical Stage
核心洞察
UKHSA (搜索) and Stablepharma (搜索)'s thermostable tetanus (搜索) and diphtheria (搜索) vaccine SPVX02 (搜索) completed Phase 1 trials, demonstrating effectiveness after 24 months of storage at 30°C without refrigeration.
The vaccine addresses critical global immunization challenges, as WHO estimates up to half of all vaccines fail to reach recipients due to cold chain maintenance difficulties.
SPVX02 (搜索) will advance to larger Phase 2 trials comparing its effectiveness to licensed European vaccines, with potential to revolutionize vaccine distribution in remote areas and emergency situations.
Scientists from the UK Health Security Agency (UKHSA (搜索)) have achieved a significant breakthrough in vaccine technology with the successful completion of Phase 1 trials for SPVX02 (搜索), a thermostable tetanus (搜索) and diphtheria (搜索) vaccine that maintains effectiveness without refrigeration. The vaccine, developed by UK pharmaceutical company Stablepharma (搜索) Ltd, remained effective even after long-term storage at 30°C for 24 months, according to evaluation results conducted at UKHSA's Vaccine Development and Evaluation Centre (VDEC).
Clinical Development Progress
SPVX02 (搜索) will now advance to the next stage of clinical trials, involving a larger cohort of healthy participants in a comparative study against vaccines already licensed for use in Europe. The upcoming trials are expected to be conducted at clinical study sites across the UK over the coming months, with UKHSA (搜索) continuing to provide support by testing immune responses to the vaccines administered to study participants.
Addressing Global Vaccine Distribution Challenges
The development addresses one of the most significant barriers to meeting global immunization targets. Most vaccines require storage at constant cold temperatures from manufacture to administration, a system known as the "cold chain." When this chain is broken, vaccines can lose effectiveness and must be discarded. The World Health Organization (WHO) estimates that up to half of all vaccines do not reach their intended recipients, citing cold chain maintenance difficulties as a major reason for this wastage.
Cold chain maintenance presents particular challenges in remote areas, during natural disasters, or in countries with unreliable electricity supplies. A vaccine that eliminates cold chain requirements could dramatically reduce wastage, simplify distribution, and make immunization programmes more resilient, especially in developing world contexts and emergency response situations.
Industry and Academic Collaboration
The SPVX02 (搜索) programme represents a collaborative effort between the UK biotech industry, government, and academia, with support from Innovate UK (搜索) and the National Institute for Health and Care Research (NIHR (搜索)) Southampton Clinical Research Facility. This partnership demonstrates the potential for coordinated efforts to improve vaccine access, reduce waste, and strengthen global health resilience.
Expert Perspectives
Dr Bassam Hallis OBE, Deputy Director and lead for the Vaccine Development and Evaluation Centre at UKHSA (搜索), emphasized the broader implications of the technology: "The progress in fridge-free vaccine technology is an excellent example of the huge contribution that the UK continues to make to transform public health through innovative technological and scientific advances. Fridge free vaccines could provide significant benefits for vaccine delivery and deployment across the world, particularly in areas where limitations in infrastructure make maintaining a cold chain more challenging."
Dr Karen O'Hanlon, Chief Operating Officer at Stablepharma (搜索) and SPVX02 (搜索) programme lead, highlighted the multifaceted benefits of the approach: "Vaccines that do not require refrigeration at any point, from manufacture to deployment, offer a clear path to a more equitable, resilient, and sustainable healthcare system. They represent not just a scientific innovation, but a public health and climate solution—especially as we prepare for future pandemics and strive toward universal vaccine coverage."
Professor Saul Faust, Director of the NIHR (搜索) Southampton Clinical Research Facility, noted the significance of the collaborative model: "The NIHR Clinical Research Facility and UKHSA (搜索) collaboration with Stablepharma (搜索) has accelerated the translation of this technology from laboratory science to potential patient impact and reinforces the leading role that the UK plays globally in vaccine research, development, deployment and evaluation."